Advertisement

DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare · USD

Set alert

Price alert · DNA

All alert types
11.21 USD -1.53 -12.01%
As of Oct 30, 2026 Extended hours 11.34 +1.16%
Bid
11.22 × 2,500
Ask
11.24 × 200
10.61 Day range 12.61
5.48 52-week range 14.98
YTD
+34.90%
1 year
-6.66%
Open
12.12
Prev close
12.74
Mkt cap
754.88M
Vol
2.73M
Avg vol
2.19M
EPS
-5.06
P/E
0.00
Div yield
0.00%
More statistics
Low
10.61
High
12.61
Forward P/E
-5.17
Beta
1.79
Short ratio
6.35
Inst. own
73.73%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
8.08
200-d avg
8.32
1y target
7.00

5D chart

Chart tools
Interval
DNA five-day price chart9.6910.811.812.914.0Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
1.01B
Enterprise value
933.60M
Trailing P/E
0.00
Forward P/E
-5.17
PEG ratio
0.00
Price / sales
7.62
Price / book
2.27
EPS (TTM)
-5.06
Beta
1.79
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-219.61%
Revenue (TTM)
132.42M
Revenue growth
-48.50%
Free cash flow
-72.40M
Total cash
302.16M
Total debt
404.11M
Return on equity
-59.94%
Shares outstanding
55.38M
Short % of float
13.36%
50-day average
8.08
200-day average
8.32

Analyst view

Consensus: none

Price target (mean) 7.00 -37.6% downside
Target (low)
5.00
Target (mean)
7.00
Target (high)
9.00
Ratings (0m) 3 0 buy · 1 hold · 2 sell
  • Strong buy0
  • Buy0
  • Hold1
  • Sell1
  • Strong sell1

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.58.

Earnings history

Financials — quick view

All financials
DNA Revenue — quarterly 20.16M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNA Net income — quarterly -46.71M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNA EPS — quarterly -0.75
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.58———
Aug 5, 2026Jun 30, 2026-0.895-0.75+0.15+16.20%
May 7, 2026Mar 31, 2026-1.21-1.39-0.18-14.77%
Feb 26, 2026Dec 31, 2025-1.80-1.42+0.38+21.11%
Nov 6, 2025Sep 30, 2025-1.24-1.45-0.21-16.94%
Aug 7, 2025Jun 30, 2025-1.44-1.10+0.34+23.61%

Upgrades / downgrades

DNA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 4, 2026BTIGreitSellSell
Aug 7, 2026TD CowendownBuyHold
Mar 12, 2026BTIGmainSellSell
Jan 8, 2026TD CowenmainBuyBuy
Aug 25, 2025BTIGmainSellSell
Sep 20, 2024TD CowenmainBuyBuy

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ginkgo.bio

News

Your note

Sign in to keep a note on DNA — it syncs with the Stock Master app.

Insider holders

DNA insider holders
InsiderRelationLatest transactionDateShares held
CANTON BARTHOLOMEWBeneficial Owner of more than 10% of a Class of SecuritySaleApr 9, 20260
COEN STEVEN P.Chief Financial OfficerSaleAug 23, 202651,851
DMYTRUK MARK EChief Financial OfficerSaleMay 20, 202546,226
HANNAN KATHY HOPINKAHDirectorConversion of Exercise of derivative securityJun 10, 202515,003
HENRY CHRISTIAN ODirectorSaleSep 14, 202619,310
KELLY JASON RChief Executive OfficerSaleApr 8, 2026316,483

Institution ownership

DNA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.73%4,282,90364.16MJun 29, 2026
Viking Global Investors, L.P.6.46%3,577,12853.59MJun 29, 2026
Erste Asset Management GmbH4.58%2,536,93938.00MJun 29, 2026
BAILLIE GIFFORD & CO4.32%2,391,64935.83MJun 29, 2026
Vanguard Capital Management LLC3.77%2,087,29331.27MJun 29, 2026
Anchorage Capital Group, LLC3.15%1,746,36326.16MJun 29, 2026

Fund ownership

DNA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.69%1,489,85122.32MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.23%1,232,83218.47MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.99%550,0718.24MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.94%523,1477.84MJul 30, 2026
PIMCO Equity Series-PIMCO RAE US Small Fund0.91%506,3127.58MJun 29, 2026
iShares Trust-iShares Russell 2000 Value ETF0.80%441,7786.62MAug 30, 2026
Advertisement